Bicara Therapeutics Inc. Common Stock (BCAX) Stock

Bicara Therapeutics Inc. Common Stock (BCAX) is a Healthcare stock trading at $23.20 (as of 2026-06-18), with a market capitalization of $1.31B and a trailing P/E of -7.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeted monoclonal antibody with a domain that binds human transforming growth factor beta, intended for solid tumor treatment.

Valuation — source: SEC EDGAR (first-party)
Price	$23.20
Market Cap	$1.31B
P/E Ratio	-7.8
EV / EBITDA	-6.3
Price / Book	2.77
Price / Sales	84.13
DCF Value (model)	$-26.38
DCF Upside vs Price	-213.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$17.87M
Net Margin	-771.9%
Return on Equity	-30.6%
Current Ratio	13.85
Revenue Growth (YoY)	22.6%
EPS Growth (YoY)	-37.8%
FCF Growth (YoY)	43.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	29.63 (safe)

Valuation vs Sector & Industry
Stock P/E	-7.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-137.4%
vs Industry	-145.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($144.32M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Claire Mazumdar Clemon
Employees	55
Country	US
IPO Date	2024-09-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.